Edgewise Therapeutics, Inc. Cash Flow Statement

Cash Flow Statement Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Operating Activities
Depreciation and Depletion 0.20M0.30M0.40M1.60M2.10M
Share-based Compensation 0.35M4.40M10.92M17.56M24.71M
Gains from Investment Securities 0.06M4.30M1.49M1.11M30.30M
Cash from Operations -14.63M-33.51M-52.63M-91.95M-109.03M
Depreciation, Depletion & Amortization
Amortizatization of Intangibles 0.54M9.52M12.54M
Depreciation & Amortization (CF) 0.20M0.30M0.40M1.60M2.10M
Change in Working Capital
Change in Account Payables 0.52M2.65M0.05M-0.09M1.74M
Change in Accured Expenses 1.00M2.75M1.34M1.66M4.36M
Other Working Capital Changes 0.42M2.39M2.92M3.55M-3.29M
Investing Activities
Capital Expenditures 0.20M0.67M5.55M5.75M1.31M
Change in Acquisitions & Divestments 43.20M196.78M344.38M277.92M
Cash from Investing Activities -24.38M-242.23M-70.58M102.89M-184.66M
Financing Activities
Other financing activities 0.12M0.25M0.17M9.48M
Cash from Financing Activities 120.28M186.38M129.64M53.17M249.25M
Additional items
Change in Cash 81.26M-89.35M6.43M64.10M-44.43M
Free Cash Flow -14.84M-34.17M-58.18M-97.69M-110.34M
Net Cash Flow 81.26M-89.35M6.43M64.10M-44.43M